# Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Study · id `cardio:ct-nct02722265` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02722265](<https://clinicaltrials.gov/study/NCT02722265>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02722265

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 368 participants.

## Technical summary

Registry record NCT02722265. Allocation not applicable; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2017-07-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 368 participants (enrolled count; ClinicalTrials.gov record NCT02722265, source copy `cardio:ctgov-nct02722265-2019-10-08`, retrieved 2026-10-26)
- Start date: 2016-03 (registry gives no type) (ClinicalTrials.gov record NCT02722265, source copy `cardio:ctgov-nct02722265-2019-10-08`, retrieved 2026-10-26)
- Primary completion: 2017-07-08 (actual) (ClinicalTrials.gov record NCT02722265, source copy `cardio:ctgov-nct02722265-2019-10-08`, retrieved 2026-10-26)
- Completion: 2017-07-08 (actual) (ClinicalTrials.gov record NCT02722265, source copy `cardio:ctgov-nct02722265-2019-10-08`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02722265, source copy `cardio:ctgov-nct02722265-2019-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02722265-2019-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): CS-3150
- Lead sponsor: Daiichi Sankyo Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo Co., Ltd. (`cardio:org-daiichi-sankyo-co-ltd`)

## Provenance

Content hash: c015fa2fc7249a8c16d407b2bcbf39a0e497926c9e4bbd471ef71165e4842c46
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
